ZYME Quote, Financials, Valuation and Earnings

Regeneron Pharmaceuticals, Inc. has a net margin of -70.99% compared to Zymeworks, Inc.'s net margin of 21.74%. Zymeworks, Inc.'s return on equity of -18.82% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Zymeworks, Inc. has a consensus price target of $36.46, signalling upside risk potential of 56.56%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $869.96 which suggests that it could grow by 11.3%. Given that Zymeworks, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Zymeworks, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Zymeworks, Inc. has a beta of 1.245, which suggesting that the stock is 24.531% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Zymeworks, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.94 per share. Zymeworks, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zymeworks, Inc. quarterly revenues are $27.6M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Zymeworks, Inc.'s net income of -$19.6M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Zymeworks, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks, Inc. is 13.12x versus 5.92x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Scholar Rock Holding Corp. has a net margin of -70.99% compared to Zymeworks, Inc.'s net margin of --. Zymeworks, Inc.'s return on equity of -18.82% beat Scholar Rock Holding Corp.'s return on equity of -142.69%.

Zymeworks, Inc. has a consensus price target of $36.46, signalling upside risk potential of 56.56%. On the other hand Scholar Rock Holding Corp. has an analysts' consensus of $50.36 which suggests that it could grow by 13.75%. Given that Zymeworks, Inc. has higher upside potential than Scholar Rock Holding Corp., analysts believe Zymeworks, Inc. is more attractive than Scholar Rock Holding Corp..

Zymeworks, Inc. has a beta of 1.245, which suggesting that the stock is 24.531% more volatile than S&P 500. In comparison Scholar Rock Holding Corp. has a beta of 0.671, suggesting its less volatile than the S&P 500 by 32.859%.

Zymeworks, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scholar Rock Holding Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks, Inc. pays -- of its earnings as a dividend. Scholar Rock Holding Corp. pays out -- of its earnings as a dividend.

Zymeworks, Inc. quarterly revenues are $27.6M, which are larger than Scholar Rock Holding Corp. quarterly revenues of --. Zymeworks, Inc.'s net income of -$19.6M is higher than Scholar Rock Holding Corp.'s net income of -$102.2M. Notably, Zymeworks, Inc.'s price-to-earnings ratio is -- while Scholar Rock Holding Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks, Inc. is 13.12x versus 72.82x for Scholar Rock Holding Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics, Inc. has a net margin of -70.99% compared to Zymeworks, Inc.'s net margin of -360.68%. Zymeworks, Inc.'s return on equity of -18.82% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.

Zymeworks, Inc. has a consensus price target of $36.46, signalling upside risk potential of 56.56%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $41.70 which suggests that it could grow by 14.53%. Given that Zymeworks, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Zymeworks, Inc. is more attractive than Stoke Therapeutics, Inc..

Zymeworks, Inc. has a beta of 1.245, which suggesting that the stock is 24.531% more volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.101, suggesting its more volatile than the S&P 500 by 10.054%.

Zymeworks, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.

Zymeworks, Inc. quarterly revenues are $27.6M, which are larger than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Zymeworks, Inc.'s net income of -$19.6M is higher than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Zymeworks, Inc.'s price-to-earnings ratio is -- while Stoke Therapeutics, Inc.'s PE ratio is 55.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks, Inc. is 13.12x versus 10.33x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -70.99% compared to Zymeworks, Inc.'s net margin of 36.91%. Zymeworks, Inc.'s return on equity of -18.82% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.

Zymeworks, Inc. has a consensus price target of $36.46, signalling upside risk potential of 56.56%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $532.96 which suggests that it could grow by 7.27%. Given that Zymeworks, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Zymeworks, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Zymeworks, Inc. has a beta of 1.245, which suggesting that the stock is 24.531% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.

Zymeworks, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Zymeworks, Inc. quarterly revenues are $27.6M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Zymeworks, Inc.'s net income of -$19.6M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Zymeworks, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks, Inc. is 13.12x versus 10.62x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.